AC
IONS icon

Aristides Capital’s Ionis Pharmaceuticals IONS Stock Holding History

Aristides Capital’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-6,891
Closed -$255K – 167
2022
Q2 		$255K Hold
6,891
– – 0.17% 111
2022
Q1 		$255K Buy
+6,891
New +$226K 0.16% 125

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Aristides Capital's IONS Position: Q3 2022 in Review

Aristides Capital sold out of Ionis Pharmaceuticals (IONS) in Q3 2022, closing a stake of 6,891 shares — an estimated $255K sold.

Aristides Capital first reported a position in IONS in Q1 2022 and held it in 2 quarters. The position peaked at $255K in Q2 2022. 349 funds tracked by Wall St. Rank hold IONS as of Q3 2022.

  • Aristides Capital reported no remaining Ionis Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
  • Aristides Capital sold 6,891 Ionis Pharmaceuticals shares in Q3 2022, an estimated $255K.
  • Aristides Capital first reported a position in Ionis Pharmaceuticals in Q1 2022 and held it in 2 quarters.
  • Aristides Capital's Ionis Pharmaceuticals position peaked at $255K in Q2 2022.
  • 349 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q3 2022.

Based on Aristides Capital's 13F filing for Q3 2022, filed 15 Nov 2022.